Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTXCUS)

Drug Name

Galiximab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Activation B7-1 antigen (CD80)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abatacept	DMSA8RU	Alopecia areata	ED70.2	Approved	[3]
RhuDex	DMGM1IR	Rheumatoid arthritis	FA20	Phase 2a	[4]
HS-110	DML4RCG	Non-small-cell lung cancer	2C25.Y	Phase 2	[5]
MAXY-4	DMMP7XG	Autoimmune diabetes	5A10	Phase 1	[6]
CAR-T cells targeting CD80/86	DM6Z7AD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
Tolerimab	DMZKIE0	Transplant rejection	NE84	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health.
2	Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.
3	Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8.
4	A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
5	Clinical pipeline report, company report or official report of Heat Biologics.
6	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3.
7	ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers
8	US patent application no. 2004,0171,123, Albumin fusion proteins.